Incyte Corporation (INCY)
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INCY or MYGN: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Incyte (INCY) and Myriad Genetics (MYGN). But which of these two companies is the best option for those looking for undervalued stocks?
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
Incyte (INCY) jumped 19.6% in the past three months as investors appreciated the stock grants and buyback plan.
The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024
Cathie Wood was the hottest money manager in the game in 2020. Her Ark Invest family of funds offered investors blistering returns on their money.
Incyte: The Worst Has Been Avoided
In recent months, Incyte's management has continued to delight investors by accelerating the pace of development of its anti-inflammatory treatments. On May 30, 2024, Incyte announced the completion of its acquisition of Escient Pharmaceuticals for $750 million. Sales of Opzelura, one of the company's gems, totaled $85.7 million in the first quarter of 2024, up 51.4% year-on-year.
Incyte (INCY) Up 7.5% Since Last Earnings Report: Can It Continue?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week
Incyte (INCY) rises 7% in a week as investors appreciated the company's buyback plan to boost returns.
